Gene and Cell Therapy – News and Features

News
Mouse Studies Show Gene Therapy Method Holds Promise in Targeting Tumor Blood Vessels for Destruction
Cancer researchers develop method for delivering a therapeutic gene specifically to the blood vessels of tumors in mice.

News
BioLife Solutions Completes Safety Studies on HypoThermosol® and CryoStor™
The studies evaluated injections of HypoThermosol, CryoStor, or control phosphate buffered saline into healthy rodents.

News
Novocell Announces Collaboration with Renowned Stem Cell Researcher of Kyoto University
The collaboration with Kyoto researcher will allow Novocell to explore the creation of human islet cells from induced pluripotent stem cells.

News
A Novel Human Stem Cell-Based Model of ALS Opens Doors for Rapid Drug Screening
A study at the Salk Institute confirmed that dysfunctional human astrocytes turn against their charges and kill off healthy motor neurons.

News
Alnylam Announces Acquisition of Nucleonics Patent Assets
The acquisition expands Alnylam intellectual property estate, includes several early and broad RNAi patent families.

News
Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials
The collaboration aims to advance development of Neuralstem's human spinal cord neural stem cell therapies.

News
Horizon Secures World-Wide Exclusive Patent Position on Core GENESIS™ Platform
Horizon gains world-wide exclusive rights to a key genetic process behind its GENESIS platform used to create X-MAN cell-lines.

News
Cryo-Cell Announces Partnership with National Institutes of Health
The collaboration will evaluate menstrual stem cells for future potential breast cancer therapy.

News
Geron Scientists and Collaborators Demonstrate TAT2 Enhances Antiviral Function of Immune Cells From HIV+ Donors
Geron Corporation announced the publication of preclinical data on TAT2, a small molecule telomerase activator.

News
Incyte’s JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement in Rheumatoid Arthritis Patients
Incyte Corporation announced the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus kinase (JAK) inhibitor, in patients with rheumatoid arthritis (RA).
Results from the 50-patient placebo-controlled trial demonstrated that three of the four doses of INCB18424 evaluated (15 mg BID, 25 mg BID and 50 mg QD) produced impressive clinical benefits and all of the doses were well tolerated. American College of Rheumatology (ACR) 20, ACR50, ACR70 a
Advertisement